Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1964 2
1965 1
1967 2
1969 2
1972 5
1973 2
1974 5
1975 7
1976 8
1977 12
1978 13
1979 12
1980 9
1981 14
1982 13
1983 19
1984 19
1985 19
1986 22
1987 16
1988 16
1989 23
1990 20
1991 30
1992 20
1993 41
1994 26
1995 14
1996 28
1997 19
1998 28
1999 17
2000 24
2001 24
2002 16
2003 19
2004 47
2005 41
2006 39
2007 43
2008 66
2009 83
2010 102
2011 98
2012 97
2013 112
2014 131
2015 115
2016 100
2017 113
2018 116
2019 129
2020 131
2021 140
2022 157
2023 137
2024 115
2025 142

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,525 results

Results by year

Filters applied: . Clear all
Page 1
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakamura H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Chida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H. Kumagai S, et al. Cancer Cell. 2022 Feb 14;40(2):201-218.e9. doi: 10.1016/j.ccell.2022.01.001. Epub 2022 Jan 28. Cancer Cell. 2022. PMID: 35090594 Free article.
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.
Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A. Casadei-Gardini A, et al. Eur J Cancer. 2023 Feb;180:9-20. doi: 10.1016/j.ejca.2022.11.017. Epub 2022 Nov 25. Eur J Cancer. 2023. PMID: 36527976 Clinical Trial.
Efficacy and Safety of Intravenous-to-Oral Lascufloxacin Switch Therapy in Community-Onset Pneumonia: A Single-Arm, Open-Label Clinical Trial.
Iwanaga N, Hosogaya N, Takazono T, Tsukamoto Y, Morio R, Irifune S, Miyamura T, Harada Y, Nagayoshi Y, Kondo A, Mihara T, Kohno Y, Fukuda Y, Kobayashi T, Sasaki E, Sawai T, Imamura Y, Morikawa T, Hashiguchi K, Futsuki Y, Inoue Y, Fukushima K, Suyama N, Senju H, Tanaka H, Kawazoe Y, Morimoto S, Ito Y, Yoshida M, Takeda K, Ide S, Sakamoto N, Izumikawa K, Yanagihara K, Mukae H. Iwanaga N, et al. Cureus. 2025 Mar 11;17(3):e80404. doi: 10.7759/cureus.80404. eCollection 2025 Mar. Cureus. 2025. PMID: 40078884 Free PMC article.
The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine.
Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, Ozaki H, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Taniguchi H, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Otsuka T, Hara H, Okano N, Nishina T, Sakamoto Y, Miki I, Kobayashi S, Yuda J, Kageyama SI, Nagamine M, Sakashita S, Sakamoto N, Yamashita R, Koga Y, Bando H, Ishii G, Kuwata T, Park WY, Ohtsu A, Yoshino T. Hashimoto T, et al. Cancer Discov. 2024 Nov 1;14(11):2243-2261. doi: 10.1158/2159-8290.CD-24-0206. Cancer Discov. 2024. PMID: 39023403 Free PMC article.
Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer.
Takei S, Tanaka Y, Lin YT, Koyama S, Fukuoka S, Hara H, Nakamura Y, Kuboki Y, Kotani D, Kojima T, Bando H, Mishima S, Ueno T, Kojima S, Wakabayashi M, Sakamoto N, Kojima M, Kuwata T, Yoshino T, Nishikawa H, Mano H, Endo I, Shitara K, Kawazoe A. Takei S, et al. J Immunother Cancer. 2024 Feb 8;12(2):e008210. doi: 10.1136/jitc-2023-008210. J Immunother Cancer. 2024. PMID: 38336371 Free PMC article.
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study.
Persano M, Casadei-Gardini A, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Mascia L, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Rimini M. Persano M, et al. Oncology. 2025;103(6):456-468. doi: 10.1159/000541018. Epub 2024 Oct 11. Oncology. 2025. PMID: 39396495 Free article.
Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD.
Kaneko K, Kuroda H, Matsumoto Y, Sakamoto N, Yamazaki N, Yamamoto N, Umezawa S, Namatame C, Ono H, Takai Y, Takahashi T, Fujimori J, Nakashima I, Harigaya Y, Lassmann H, Fujihara K, Misu T, Aoki M. Kaneko K, et al. Neurol Neuroimmunol Neuroinflamm. 2024 Sep;11(5):e200293. doi: 10.1212/NXI.0000000000200293. Epub 2024 Aug 12. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 39133885 Free PMC article.
MS-DIAL 5 multimodal mass spectrometry data mining unveils lipidome complexities.
Takeda H, Matsuzawa Y, Takeuchi M, Takahashi M, Nishida K, Harayama T, Todoroki Y, Shimizu K, Sakamoto N, Oka T, Maekawa M, Chung MH, Kurizaki Y, Kiuchi S, Tokiyoshi K, Buyantogtokh B, Kurata M, Kvasnička A, Takeda U, Uchino H, Hasegawa M, Miyamoto J, Tanabe K, Takeda S, Mori T, Kumakubo R, Tanaka T, Yoshino T, Okamoto M, Takahashi H, Arita M, Tsugawa H. Takeda H, et al. Nat Commun. 2024 Nov 28;15(1):9903. doi: 10.1038/s41467-024-54137-w. Nat Commun. 2024. PMID: 39609386 Free PMC article.
2,525 results